Treatment of refractory rheumatoid arthritis with a monoclonal antibody to intercellular adhesion molecule 1

Arthur F. Kavanaugh, Laurie S. Davis, Lisa A. Nichols, Stephen H. Norris, Robert Rothlein, Linda A. Scharschmidt, Peter E. Lipsky

Research output: Contribution to journalArticle

252 Scopus citations

Abstract

Objective. To assess the safety and efficacy of a monoclonal antibody (MAb) to intercellular adhesion molecule 1 (ICAM-1; CD54) in rheumatoid arthritis (RA). Methods. A phase I/II, open-label, dose-escalation study of 32 patients. Results. During treatment, a peripheral CD3+/CD4+ lymphocytosis was noted, and several patients demonstrated transient cutaneous anergy, which suggests that therapy modified T cell recirculation. Thirteen of the 23 patients who received 5 days of treatment demonstrated clinical improvement through day 29, and 9 of 23 through day 60. Adverse effects were minor and transient. Conclusion. Anti-ICAM-1 MAb therapy was well tolerated, resulted in a transient alteration in T lymphocyte recirculation, and effected clinical improvement in some RA patients.

Original languageEnglish (US)
Pages (from-to)992-999
Number of pages8
JournalArthritis and Rheumatism
Volume37
Issue number7
DOIs
Publication statusPublished - Jul 1994

    Fingerprint

ASJC Scopus subject areas

  • Immunology
  • Rheumatology

Cite this

Kavanaugh, A. F., Davis, L. S., Nichols, L. A., Norris, S. H., Rothlein, R., Scharschmidt, L. A., & Lipsky, P. E. (1994). Treatment of refractory rheumatoid arthritis with a monoclonal antibody to intercellular adhesion molecule 1. Arthritis and Rheumatism, 37(7), 992-999. https://doi.org/10.1002/art.1780370703